PMID: 8581413Sep 1, 1995Paper

The effects of combined treatment with the novel vitamin D analogue MC 1288 and cyclosporine A on cardiac allograft survival

Transplant Immunology
C JohnssonG Tufveson

Abstract

The efficacy of combined treatment with the novel vitamin D analogue MC 1288 (20-epi-1 alpha,25-dihydroxycholecalciferol) and cyclosporine A (CyA) in preventing rejection following organ transplantation was evaluated in the heterotopic cardiac allograft model. Wistar/Kyoto rats received hearts from PVG donors and were subsequently treated with MC 1288 and CyA in various dose combinations. Administration of MC 1288 0.1 microgram/kg together with CyA 5 mg/kg produced significantly prolonged graft survival times as compared with single therapy with MC 1288 0.1 microgram/kg (p < 0.01) or CyA 5 mg/kg (p < 0.001). MC 1288 and CyA were tested also in combination with the immunomodulating drug LS-2616, which, in several laboratories, is used as a model for the evaluation of new combinations of immunosuppressive drugs. LS-2616 abolishes the immunosuppressive effect of CyA and the transplanted hearts are thus rejected at the same time as grafts of untreated recipients, i.e. on day 8. The immunosuppressive effect of MC 1288 is also counteracted by LS-2616, but the effect is not absolute and the median graft survival time is 11.0 days. Combined treatment with MC 1288 and CyA in the presence of LS-2616 resulted in a median graft survival ti...Continue Reading

References

Apr 1, 1992·Immunology Today·S L Schreiber, G R Crabtree
Dec 1, 1990·Bone and Mineral·R Vieth
Jul 1, 1989·The Journal of Clinical Endocrinology and Metabolism·C D TsoukasS C Manolagas
Apr 13, 1989·The New England Journal of Medicine·H ReichelA W Norman
Aug 1, 1986·The Journal of Clinical Endocrinology and Metabolism·S C ManolagasL J Deftos
May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·H ReichelA W Norman
Mar 1, 1986·Seminars in Nephrology
Sep 16, 1983·Science·D M ProvvediniS C Manolagas
Oct 1, 1984·The Journal of Clinical Investigation·W F RigbyM W Fanger
Jan 1, 1994·Transplant International : Official Journal of the European Society for Organ Transplantation·C Johnsson, G Tufveson

❮ Previous
Next ❯

Citations

Aug 1, 2000·Indian Journal of Clinical Biochemistry : IJCB·H LaiS K Aggarwal
Apr 21, 2006·Transplant International : Official Journal of the European Society for Organ Transplantation·Michel VierboomMargreet Jonker
Nov 10, 2011·Diabetes/metabolism Research and Reviews·Gabriela Bomfim FerreiraChantal Mathieu
Jul 31, 2001·Bone Marrow Transplantation·I PakkalaA Räisänen-Sokolowski
Apr 5, 2001·Clinical Immunology : the Official Journal of the Clinical Immunology Society·M Linker-IsraeliH P Koeffler
Jun 17, 2008·Molecular Aspects of Medicine·Alex J Brown, Eduardo Slatopolsky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.